Published in Hepatitis Weekly, December 25th, 2006
Study 1: Recent research from Italy published in the Journal of Hepatology chronicled the comparison of entecavir versus lamivudine for hepatitis B e antigen (HbeAg) positive and negative chronic hepatitis B.
"Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2. studies in patients with HBeAg-negative chronic hepatitis B," wrote P. Lampertico and colleagues, University of Milan.
"In this phase 3, double-blind trial, we randomly assigned 648 patients with HBeAg-negative chronic hepatitis B who had not...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.